Table of Content - Irritable Bowel Syndrome Treatment Market Growth, Trends 2032

Market Segmentation

Irritable Bowel Syndrome Treatment Type Outlook (USD Billion, 2019-2030)

IBS-D

IBS-C

IBS-M

Irritable Bowel Syndrome Treatment Drug Type Outlook (USD Billion, 2019-2030)

Lubiprostone

Linaclotide

Rifaximin

Eluxadoline

Alosetron

Irritable Bowel Syndrome Treatment End-User Outlook (USD Billion, 2019-2030)

Hospitals

Clinics

Research Laboratories

Others

Irritable Bowel Syndrome Treatment Regional Outlook (USD Billion, 2019-2030)

North America Outlook (USD Billion, 2019-2030)
- North America Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- North America Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- North America Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- US Outlook (USD Billion, 2019-2030)
- US Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- US Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- US Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- CANADA Outlook (USD Billion, 2019-2030)
- CANADA Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- CANADA Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- CANADA Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others

Europe Outlook (USD Billion, 2019-2030)
- Europe Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Europe Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Europe Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Germany Outlook (USD Billion, 2019-2030)
- Germany Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Germany Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Germany Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- France Outlook (USD Billion, 2019-2030)
- France Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- France Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- France Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- UK Outlook (USD Billion, 2019-2030)
- UK Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- UK Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- UK Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- ITALY Outlook (USD Billion, 2019-2030)
- ITALY Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- ITALY Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- ITALY Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- SPAIN Outlook (USD Billion, 2019-2030)
- Spain Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Spain Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Spain Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Rest Of Europe Outlook (USD Billion, 2019-2030)
- Rest Of Europe Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- REST OF EUROPE Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- REST OF EUROPE Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others

Asia-Pacific Outlook (USD Billion, 2019-2030)
- Asia-Pacific Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Asia-Pacific Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Asia-Pacific Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- China Outlook (USD Billion, 2019-2030)
- China Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- China Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- China Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Japan Outlook (USD Billion, 2019-2030)
- Japan Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Japan Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Japan Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- India Outlook (USD Billion, 2019-2030)
- India Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- India Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- India Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Australia Outlook (USD Billion, 2019-2030)
- Australia Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Australia Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Australia Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)
- Rest of Asia-Pacific Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Rest of Asia-Pacific Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Rest of Asia-Pacific Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others

Rest of the World Outlook (USD Billion, 2019-2030)
- Rest of the World Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Rest of the World Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Rest of the World Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Middle East Outlook (USD Billion, 2019-2030)
- Middle East Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Middle East Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Middle East Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Africa Outlook (USD Billion, 2019-2030)
- Africa Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Africa Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Africa Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others
- Latin America Outlook (USD Billion, 2019-2030)
- Latin America Irritable Bowel Syndrome Treatment by Type
  - IBS-D
  - IBS-C
  - IBS-M
- Latin America Irritable Bowel Syndrome Treatment by Drug Type
  - Lubiprostone
  - Linaclotide
  - Rifaximin
  - Eluxadoline
  - Alosetron
- Latin America Irritable Bowel Syndrome Treatment by End-User
  - Hospitals
  - Clinics
  - Research Laboratories
  - Others

Leading companies partner with us for data-driven Insights

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

1 Report Prologue

2 Executive Summary

3 Market Introduction

3.1 Definition 18

3.2 Scope of the Study 18

3.3 List of Assumptions 19

3.4 Market Structure 19

4 Research Methodology

4.1 Research Process 21

4.2 Primary Research 22

4.3 Secondary Research 23

4.4 Market Size Estimation 23

4.5 Forecast Model 24

5 Market Dynamics

5.1 Introduction 26

5.2 Drivers 27

5.2.1 Rising Prevalence of Anxiety 27

5.2.2 Strong Drug Pipeline 27

5.2.3 Increasing Prevalence of Depression 27

5.3 Restraints 28

5.3.1 Stringent Government Regulations 28

5.3.2 Limited Patient Satisfaction with IBS Treatment Provided by Healthcare Professionals 28

5.4 Opportunities 28

5.4.1 Increasing Reimbursement for IBS 28

6 Market Factor Analysis

6.1 Porter’s Five Forces Model 30

6.1.1 Bargaining Power of Suppliers 31

6.1.2 Bargaining Power of Buyers 31

6.1.3 Threat of New Entrants 31

6.1.5 Intense Rivalry 31

6.2 Value chain analysis 32

6.2.1 Research and Development 32

6.2.2 Manufacturing 32

6.2.3 Distribution & Sales 32

6.2.4 Post-Sales Monitoring 32

7 Global Irritable Bowel Syndrome Treatment Market by Type

7.1 Overview 34

7.2 IBS-D 35

7.3 IBS-C 35

7.4 IBS-M 36

8 Global Irritable Bowel Syndrome Treatment Market by Drug Type

8.1 Overview 38

8.2 Lubiprostone 39

8.3 Linaclotide 39

8.4 Eluxadoline 40

8.5 Rifaximin 40

8.6 Alosetron 41

8.7 Others 41

9 Global Irritable Bowel Syndrome Treatment Market by End-user

9.1 Overview 43

9.2 Hospitals 44

9.3 Clinics 44

9.4 Research Laboratories 45

9.5 Others 45

10 Global Irritable Bowel Syndrome Treatment Market by Region

10.1 Overview 47

10.2 Americas 49

10.2.1 North America 50

10.2.1.1 US 52

10.2.1.2 Canada 53

10.2.2 South America 54

10.3 Europe 56

10.3.1 Western Europe 57

10.3.1.1 Germany 59

10.3.1.2 France 60

10.3.1.3 UK 61

10.3.1.4 Italy 62

10.3.1.5 Spain 63

10.3.1.6 Rest of Western Europe 64

10.3.2 Eastern Europe 65

10.4 Asia-Pacific 67

10.4.1 Japan 69

10.4.2 China 70

10.4.3 India 71

10.4.4 South Korea 72

10.4.5 Australia 73

10.4.6 Rest of Asia-Pacific 74

10.5 Middle East & Africa 75

10.5.1 Middle East 76

10.5.2 Africa 77

11 Competitive Landscape

11.2 Company Market Share Analysis 80

12 Company Profiles

12.1 Abbott 83

12.1.1 Company Overview 83

12.1.2 Financial Overview 83

12.1.3 Products Offering 84

12.1.4 SWOT Analysis 84

12.1.5 Key Developments 84

12.1.6 Key strategy 84

12.2 Allergan Inc. 85

12.2.1 Company Overview 85

12.2.2 Financial Overview 85

12.2.3 Products Offering 86

12.2.4 SWOT Analysis 86

12.2.5 Key Developments 86

12.2.6 Key strategy 86

12.3 Ardelyx, Inc. 87

12.3.1 Company Overview 87

12.3.2 Financial Overview 87

12.3.3 Products Offering 87

12.3.4 SWOT Analysis 87

12.3.5 Key Developments 88

12.3.6 Key Strategy 88

12.4 Astellas Pharma, Inc. 89

12.4.1 Company Overview 89

12.4.2 Financial Overview 89

12.4.3 Products Offering 89

12.4.4 SWOT Analysis 90

12.4.5 Key Developments 90

12.4.6 Key Strategy 90

12.5 Ironwood Pharmaceuticals 91

12.5.1 Company Overview 91

12.5.2 Company Overview 91

12.5.3 Products Offering 91

12.5.4 SWOT Analysis 92

12.5.5 Key Developments 92

12.5.6 Key strategy 92

12.6 Lexicon Pharmaceuticals, Inc. 93

12.6.1 Company Overview 93

12.6.2 Financial Overview 93

12.6.3 Products Offering 93

12.6.4 SWOT Analysis 93

12.6.5 Key Development 94

12.6.6 Key Strategy 94

12.7 Mallinckrodt 95

12.7.1 Company Overview 95

12.7.2 Financial Overview 95

12.7.3 Products Offering 95

12.7.4 SWOT Analysis 96

12.7.5 Key Developments 96

12.7.6 Key strategy 96

12.8 Nestle Health Science 97

12.8.1 Company Overview 97

12.8.2 Financial Overview 97

12.8.3 Products Offering 97

12.8.4 Key Developments 98

12.8.5 SWOT Analysis 98

12.8.6 Key Strategy 98

12.9 Synergy Pharmaceuticals Inc. 99

12.9.1 Company Overview 99

12.9.2 Financial Overview 99

12.9.3 Products Offering 99

12.9.4 Key Developments 99

12.9.5 SWOT Analysis 99

12.9.6 Key Strategy 99

12.10 Valeant Pharmaceuticals International, Inc. 100

12.10.1 Company Overview 100

12.10.2 Financial Overview 100

12.10.3 Products Offering 100

12.10.4 Key Developments 101

12.10.5 SWOT Analysis 101

12.10.6 Key Strategy 101

13 Appendix

13.1 Discussion Blue Print 103

14 List of Tables

TABLE 1 MARKET SYNOPSIS 16

TABLE 2 LIST OF ASSUMPTIONS 19

TABLE 3 PRIMARY INTERVIEWS 21

TABLE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET 30

TABLE 5 GLOBAL IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 34

TABLE 6 GLOBAL IBS TREATMENT MARKET FOR IBS-D BY REGION, 2020 TO 2027 (USD MILLION) 35

TABLE 7 GLOBAL IBS TREATMENT MARKET FOR IBS-C BY REGION, 2020 TO 2027 (USD MILLION) 35

TABLE 8 GLOBAL IBS TREATMENT MARKET FOR IBS-M BY REGION, 2020 TO 2027 (USD MILLION) 36

TABLE 9 GLOBAL IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 38

TABLE 10 GLOBAL IBS TREATMENT MARKET FOR LUBIPROSTONE BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 11 GLOBAL IBS TREATMENT MARKET FOR LINACLOTIDE BY REGION, 2020 TO 2027 (USD MILLION) 39

TABLE 12 GLOBAL IBS TREATMENT MARKET FOR ELUXADOLINE BY REGION, 2020 TO 2027 (USD MILLION) 40

TABLE 13 GLOBAL IBS TREATMENT MARKET FOR RIFAXIMIN BY REGION, 2020 TO 2027 (USD MILLION) 40

TABLE 14 GLOBAL IBS TREATMENT MARKET FOR ALOSETRON BY REGION, 2020 TO 2027 (USD MILLION) 41

TABLE 15 GLOBAL IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 43

TABLE 16 GLOBAL IBS TREATMENT MARKET FOR HOSPITALS BY REGION, 2020 TO 2027 (USD MILLION) 44

TABLE 17 GLOBAL IBS TREATMENT MARKET FOR CLINICS BY REGION, 2020 TO 2027 (USD MILLION) 44

TABLE 18 GLOBAL IBS TREATMENT MARKET FOR RESEARCH LABORATORIES BY REGION, 2020 TO 2027 (USD MILLION) 45

TABLE 19 GLOBAL IBS TREATMENT MARKET BY REGION, 2020 TO 2027 (USD MILLION) 48

TABLE 20 AMERICAS IBS TREATMENT MARKET BY REGION, 2020 TO 2027 (USD MILLION) 49

TABLE 21 AMERICAS IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 49

TABLE 22 AMERICAS IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 50

TABLE 23 AMERICAS IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 50

TABLE 24 NORTH AMERICA IBS TREATMENT MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 51

TABLE 25 NORTH AMERICA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 51

TABLE 26 NORTH AMERICA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 51

TABLE 27 NORTH AMERICA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 52

TABLE 28 US IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 52

TABLE 29 US IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 52

TABLE 30 US IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 53

TABLE 31 CANADA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 53

TABLE 32 CANADA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 53

TABLE 33 CANADA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 54

TABLE 34 SOUTH AMERICA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 54

TABLE 35 SOUTH AMERICA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 54

TABLE 36 SOUTH AMERICA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 55

TABLE 37 EUROPE IBS TREATMENT MARKET BY REGION, 2020 TO 2027 (USD MILLION) 56

TABLE 38 EUROPE IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 56

TABLE 39 EUROPE IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 57

TABLE 40 EUROPE IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 57

TABLE 41 WESTERN EUROPE IBS TREATMENT MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 58

TABLE 42 WESTERN EUROPE IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 43 WESTERN EUROPE IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 58

TABLE 44 WESTERN EUROPE IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 59

TABLE 45 GERMANY IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 59

TABLE 46 GERMANY IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 59

TABLE 47 GERMANY IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 60

TABLE 48 FRANCE IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 60

TABLE 49 FRANCE IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 60

TABLE 50 FRANCE IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 61

TABLE 51 UK IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 52 UK IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 61

TABLE 53 UK IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 62

TABLE 54 ITALY IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 62

TABLE 55 ITALY IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 62

TABLE 56 ITALY IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 63

TABLE 57 SPAIN IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 58 SPAIN IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 63

TABLE 59 SPAIN IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 64

TABLE 60 REST OF WESTERN EUROPE IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 64

TABLE 61 REST OF WESTERN EUROPE IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 64

TABLE 62 REST OF WESTERN EUROPE IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 65

TABLE 63 EASTERN EUROPE IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 65

TABLE 64 EASTERN EUROPE IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 66

TABLE 65 EASTERN EUROPE IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 66

TABLE 66 ASIA-PACIFIC IBS TREATMENT MARKET BY COUNTRY, 2020 TO 2027 (USD MILLION) 67

TABLE 67 ASIA-PACIFIC IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 68

TABLE 68 ASIA-PACIFIC IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 68

TABLE 69 ASIA-PACIFIC IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 68

TABLE 70 JAPAN IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 71 JAPAN IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 69

TABLE 72 JAPAN IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 69

TABLE 73 CHINA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 70

TABLE 74 CHINA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 70

TABLE 75 CHINA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 70

TABLE 76 INDIA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 77 INDIA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 71

TABLE 78 INDIA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 71

TABLE 79 SOUTH KOREA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 72

TABLE 80 SOUTH KOREA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 72

TABLE 81 SOUTH KOREA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 72

TABLE 82 AUSTRALIA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 83 AUSTRALIA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 73

TABLE 84 AUSTRALIA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 73

TABLE 85 REST OF ASIA-PACIFIC IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 74

TABLE 86 REST OF ASIA-PACIFIC IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 74

TABLE 87 REST OF ASIA-PACIFIC IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 74

TABLE 88 MIDDLE EAST & AFRICA IBS TREATMENT MARKET BY REGION, 2020 TO 2027 (USD MILLION) 75

TABLE 89 MIDDLE EAST & AFRICA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 75

TABLE 90 MIDDLE EAST & AFRICA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 76

TABLE 91 MIDDLE EAST & AFRICA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 76

TABLE 92 MIDDLE EAST IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 76

TABLE 93 MIDDLE EAST IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 77

TABLE 94 MIDDLE EAST IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 77

TABLE 95 AFRICA IBS TREATMENT MARKET BY TYPE, 2020 TO 2027 (USD MILLION) 77

TABLE 96 AFRICA IBS TREATMENT MARKET BY DRUG TYPE, 2020 TO 2027 (USD MILLION) 78

TABLE 97 AFRICA IBS TREATMENT MARKET BY END-USER, 2020 TO 2027 (USD MILLION) 78

15 List of Figures

FIGURE 1 GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 21

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 24

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET 26

FIGURE 5 SUPPLY CHAIN: GLOBAL IRRITABLE BOWEL SYNDROME TREATMENTMARKET 32

FIGURE 6 GLOBAL IBS TREATMENT MARKET BY TYPE, 2020 & 2027 (USD MILLION) 34

FIGURE 7 GLOBAL IBS TREATMENT MARKET BY DRUG TYPE, 2020 & 2027 (USD MILLION) 38

FIGURE 8 GLOBAL IBS TREATMENT MARKET BY END-USER, 2020 & 2027 (USD MILLION) 43

FIGURE 9 GLOBAL IBS TREATMENT MARKET BY REGION, 2020 (%) 47

FIGURE 10 GLOBAL IBS TREATMENT MARKET BY REGION, 2020 & 2027 (USD MILLION) 47

FIGURE 11 AMERICAS IBS TREATMENT MARKET BY REGION, 2020 (%) 49

FIGURE 12 NORTH AMERICA IBS TREATMENT MARKET BY COUNTRY, 2020 (%) 50

FIGURE 13 EUROPE IBS TREATMENT MARKET BY REGION, 2020 (%) 56

FIGURE 14 WESTERN EUROPE IBS TREATMENT MARKET BY COUNTRY, 2020 (%) 57

FIGURE 15 ASIA-PACIFIC IBS TREATMENT MARKET BY COUNTRY, 2020 (%) 67

FIGURE 16 MIDDLE EAST & AFRICA IBS TREATMENT MARKET BY REGION, 2020 (%) 75

FIGURE 17 GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET, MARKET SHARE ANALYSIS, 2020 (%) 80

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

FEATURES	LICENCE TYPE
FEATURES	Single User	Multiuser Licence	Enterprise User
Price	$ 4,950	$ 5,950	$ 7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout The Organization.
Free Customization
Direct access to the Analyst
Deliverable Format
Deliverable Format
Platform Access
Discount on Your Next Purchase	10%	15%	10%
Printable Versions

Why Choose Market Research Future?

Leading companies partner with us for data-driven Insights